This is a demo store. No orders will be fulfilled.

iMDK - 99%, high purity , CAS No.881970-80-5

    Grade & Purity:
  • ≥99%
In stock
Item Number
I648515
Grouped product items
SKU Size
Availability
Price Qty
I648515-5mg
5mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$160.90
I648515-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$250.90
I648515-25mg
25mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$550.90
I648515-50mg
50mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$950.90
View related series
PI3K (243) PI3K/Akt/mTOR (765)

Basic Description

Specifications & Purity ≥99%
Biochemical and Physiological Mechanisms iMDK is a potent PI3K inhibitor and inhibits the growth factor MDK (also known as midkine or MK). iMDK suppresses non-small cell lung cancer (NSCLC) cooperatively with A MEK inhibitor without harming normal cells and mice.
Storage Temp Store at -20°C
Shipped In
Ice chest + Ice pads
This product requires cold chain shipping. Ground and other economy services are not available.
Product Description

iMDK is a potent PI3K inhibitor and inhibits the growth factor MDK (also known as midkine or MK). iMDK suppresses non-small cell lung cancer (NSCLC) cooperatively with A MEK inhibitor without harming normal cells and mice.

In Vitro

iMDK (50–500 nM) suppressed AKT phosphorylation in a dose-dependent manner in H441 lung adenocarcinoma cells after treatment for 72 h. In contrast, iMDK robustly increases p-ERK. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: H441 (lung adenocarcinoma; KRAS G12V ), H2009 (non-small cell carcinoma; KRAS G12A ), A549 (lung carcinoma; KRAS G12S ) and H520 (lung squamous cell carcinoma; KRAS WT ) Concentration: iMDK (2.5 μM) and PD0325901 (0.5 μM) for H441 and H2009 cells iMDK (0.125 μM) and PD0325901 (0.25 μM) for H520 cells iMDK (0.25 μM) and PD0325901 (0.125 μM) for A549 cells Incubation Time: 72 hours Result: iMDK alone did not inhibit cell viability of A549 cells, the combinatorial treatment of iMDK with PD0325901 significantly inhibited that of A549 cells compared to the single treatment of PD0325901. Western Blot AnalysisCell Line: H441 lung adenocarcinoma cells Concentration: 0-500 nM Incubation Time: 72 hours Result: Suppressed AKT phosphorylation in a dose-dependent manner. ERK1/2 phosphorylation was increased.

In Vivo

The combination treatment of iMDK ( (9 mg/kg/day; intraperitoneally injected with 100 μl) and PD0325901 (5 mg/kg; orally administered) effectively reduced lung tumor growth in a xenograft mouse model . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: female BALB/c nude mice (6 week old) bearing H441 human lung cancer xenografts Dosage: iMDK (9 mg/kg) and PD0325901 (5 mg/kg) Administration: Intraperitoneally injected with 100 μL iMDK everyday and/or orally administered PD0325901 five times per week (on days 1, 2, 3, 4, 5, 7, 8, 9, 10, 11) Result: Reduced significantly volume of the tumors derived from H441 lung adenocarcinoma cells after the combination treatment with iMDK and PD0325901 compared to that of single compound in a xenograft mouse model.

Form:Solid

Taxonomic Classification

Taxonomy Tree

Kingdom Organic compounds
Superclass Phenylpropanoids and polyketides
Class Coumarins and derivatives
Subclass Not available
Intermediate Tree Nodes Not available
Direct Parent Coumarins and derivatives
Alternative Parents 1-benzopyrans  Pyranones and derivatives  Fluorobenzenes  N-substituted imidazoles  Aryl fluorides  Thiazoles  Heteroaromatic compounds  Lactones  Oxacyclic compounds  Azacyclic compounds  Organooxygen compounds  Organonitrogen compounds  Organofluorides  Organic oxides  Hydrocarbon derivatives  
Molecular Framework Aromatic heteropolycyclic compounds
Substituents Coumarin - 1-benzopyran - Benzopyran - Halobenzene - Pyranone - Fluorobenzene - N-substituted imidazole - Aryl fluoride - Aryl halide - Pyran - Benzenoid - Monocyclic benzene moiety - Thiazole - Azole - Imidazole - Heteroaromatic compound - Lactone - Oxacycle - Azacycle - Organoheterocyclic compound - Organooxygen compound - Organic oxygen compound - Organic nitrogen compound - Hydrocarbon derivative - Organic oxide - Organonitrogen compound - Organofluoride - Organohalogen compound - Aromatic heteropolycyclic compound
Description This compound belongs to the class of organic compounds known as coumarins and derivatives. These are polycyclic aromatic compounds containing a 1-benzopyran moiety with a ketone group at the C2 carbon atom (1-benzopyran-2-one).
External Descriptors Not available

Associated Targets(Human)

PTH1R Tclin Parathyroid hormone receptor (47172 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
MTOR Tclin Serine/threonine-protein kinase mTOR (13850 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
TP53 Tchem Cellular tumor antigen p53 (48468 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
HEK293 (82097 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
EHMT2 Tchem Histone-lysine N-methyltransferase, H3 lysine-9 specific 3 (93046 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
TDP1 Tchem Tyrosyl-DNA phosphodiesterase 1 (345557 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
ERG Tbio Transcriptional regulator ERG (5589 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
CBX1 Tbio Chromobox protein homolog 1 (92434 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID

Associated Targets(non-human)

ampC Beta-lactamase AmpC (62480 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Nfe2l2 Nuclear factor erythroid 2-related factor 2 (214 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID

Mechanisms of Action

Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References

Names and Identifiers

IUPAC Name 3-[2-[(4-fluorophenyl)methyl]imidazo[2,1-b][1,3]thiazol-6-yl]chromen-2-one
INCHI InChI=1S/C21H13FN2O2S/c22-15-7-5-13(6-8-15)9-16-11-24-12-18(23-21(24)27-16)17-10-14-3-1-2-4-19(14)26-20(17)25/h1-8,10-12H,9H2
InChIKey IWFKQTWYILKFGE-UHFFFAOYSA-N
Smiles C1=CC=C2C(=C1)C=C(C(=O)O2)C3=CN4C=C(SC4=N3)CC5=CC=C(C=C5)F
Isomeric SMILES C1=CC=C2C(=C1)C=C(C(=O)O2)C3=CN4C=C(SC4=N3)CC5=CC=C(C=C5)F
PubChem CID 15991416
Molecular Weight 376.4

Certificates(CoA,COO,BSE/TSE and Analysis Chart)

C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Chemical and Physical Properties

Solubility DMSO : 3.33 mg/mL (8.85 mM; ultrasonic and warming and heat to 60°C)
Molecular Weight 376.400 g/mol
XLogP3 5.600
Hydrogen Bond Donor Count 0
Hydrogen Bond Acceptor Count 5
Rotatable Bond Count 3
Exact Mass 376.068 Da
Monoisotopic Mass 376.068 Da
Topological Polar Surface Area 71.800 Ų
Heavy Atom Count 27
Formal Charge 0
Complexity 607.000
Isotope Atom Count 0
Defined Atom Stereocenter Count 0
Undefined Atom Stereocenter Count 0
Defined Bond Stereocenter Count 0
Undefined Bond Stereocenter Count 0
The total count of all stereochemical bonds 0
Covalently-Bonded Unit Count 1

Solution Calculators

Reviews

Customer Reviews

Shall we send you a message when we have discounts available?

Remind me later

Thank you! Please check your email inbox to confirm.

Oops! Notifications are disabled.